Double biochemical modulation of 5-fluorouracil by methotrexate and levo-folinic acid in the treatment of advanced digestive tract malignancies

European Journal of Cancer Part A

Volumn 32, Issue 10, 1996, Pages 1719-1726

  Comella, P ^a,d   Palmieri, G ^a   Lorusso, V ^b   Catalano, G ^c   Nicollela, D ^e   Ianniello, G P ^e   Casaretti, R ^a   Montella, M ^a   Frasci, G ^a   Perna, M ^a   Comella, G ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

^c SECOND UNIVERSITY OF NAPLES   (Italy)

^d NATIONAL CANCER INSTITUTE   (Italy)

^e NONE

Author keywords

5 Fluorouracil; Double modulation; Gastrointestinal carcinomas; Levo folinic acid; Methotrexate; Pharmacokinetics

Indexed keywords

FLUOROURACIL; FOLINIC ACID; METHOTREXATE;

ADULT; AGED; ANEMIA; ARTICLE; CLINICAL TRIAL; DIARRHEA; DIGESTIVE SYSTEM CANCER; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; NAUSEA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; VOMITING;

EID: 0030249114     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/0959-8049(96)00155-4     Document Type: Article

References (35)

1. 1. Moertel CG. Chemotherapy of gastrointestinal cancer. N Engl J Med 1978, 299, 1049-1052.
2. 2. Grem JL, Hoth DF, Hamilton JM, King SA, Leyland-Jones B. Overview of current status and future direction on clinical trials with 5-fluorouracil in combination with folinic acid. Cancer Treat Rep 1987, 71, 1249-1253.
3. 3. Labianca R, Pancera G, Aitini E, et al. Folinic acid + 5-fluorouracil (5-FU) versus equidose 5-FU in advanced colorectal cancer. Phase III study of GISCAD (Italian Group for the Study of Digestive Tract Cancer). Ann Oncol 1991, 2, 673-679.
4. 4. Advanced Colorectal Cancer Meta-analysis Project. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer. Evidence in terms of response rate. J Clin Oncol 1992, 10, 896-903.
5. 5. Mulder JH, Smink T, Van Putten LM. 5-Fluorouracil and methotrexate combined therapy: the effect of drug scheduling. Eur J Cancer Clin Oncol 1981, 17, 831-837.
6. 6. Tattersall MHN. Current studies of methotrexate and 5-fluorouracil and their interaction in human tumor cells. Semin Oncol 1983, 10 (Suppl. 2), 6-10.
7. 7. Advanced Colorectal Cancer Meta-Analysis Project. Meta-analysis of randomized trials testing the biochemical modulation of fluorouracil by methotrexate in metastatic colorectal cancer. J Clin Oncol 1994, 12, 960-969.
8. 8. Poon MA, O'Connel MJ, Moertel CG, et al. Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol 1989, 10, 1407-1418.
9. 9. Abad A, Rosell R, Pastor MC, et al. Sequential combination of methotrexate (MTX), 5-fluorouracil (FU), and high-dose folinic acid (FA) in advanced colorectal cancer: double biochemical modulation? Am J Clin Oncol 1991, 14, 393-396.
10. 10. Romero A, Perez J, Cuevas M, et al. Double modulation (DM) of 5-fluorouracil (5-FU) by methotrexate (MTX) and high-dose (HD) L-Leucovorin (L-LV) in advanced colorectal cancer (ACC). Proc Am Soc Clin Oncol 1995, 14, 209 (abstract).
11. 11. Bertino JR, Sawicki WL, Lindquist CA. Schedule-dependent antitumor effects of methotrexate and 5-fluorouracil. Cancer Res 1977, 37, 327-328.
12. 12. Cadman ED, Heimer R, Davis L. Enhanced 5-fluorouracil nucleotide formation after methotrexate administration: explanation for drug synergism. Science 1979, 205, 1135-1137.
13. 13. Benz C, Cadman E. Modulation of 5-fluorouracil metabolism and cytotoxicity by antimetabolite pretreatment in human colorectal carcinoma HCT-8. Cancer Res 1981, 41, 994-999.
14. 14. Marsh JC, Bertino JR, Katz KH, et al. The influence of drug interval on the effect of methotrexate and fluorouracil in the treatment of advanced colorectal cancer. J Clin Oncol 1991, 9, 371-380.
15. 15. Comella P, Palmieri G, Beneduce G, et al. Significance of methotrexate serum levels achieved in patients with gastrointestinal malignancies treated with sequential methotrexate, L-folinic acid and 5-fluorouracil. Oncology 1996, 53, 198-203.
16. 16. Miller AB, Hoogstraten B, Staquet M, Winkler V. Reporting results of cancer treatment. Cancer 1981, 47, 207-214.
17. 17. Hryniuk WH, Goodyear M. The calculation of received dose intensity. J Clin Oncol 1990, 8, 1935-1937.
18. 18. Dixon WJ. BMDP Statistical Software. Berkeley, California, University of California Press, 1988.
19. 19. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958, 53, 457-481.
20. 20. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observations of each patient. II. Analysis and examples. Br J Cancer 1977, 35, 1-39.
21. 21. Cox DR. Regression models and life tables. J R Stat Soc (B) 1972, 34, 187-200.
22. 22. Gehan EA. The determination of the number of patients required in a preliminary and follow-up trial of a new chemotherapeutic agent. J Chronic Dis 1961, 13, 346-353.
23. 23. Machover D, Grison X, Goldschmidt E, et al. Fluorouracil combined with the pure (6S)-stereoisomer of folinic acid in high doses for treatment of patients with advanced colorectal carcinoma: a phase I-II study. J Natl Cancer Inst 1992, 84, 321-327.
24. 24. Rosso R, Mazzei T, Sobrero A, et al. Phase II trial of 5-fluorouracil and the natural l isomer of folinic acid in the treatment of advanced colorectal carcinoma. Eur J Cancer 1994, 30A, 338-343.
25. 25. Wils JA, Klein HO, Wagener DJTh, et al. Sequential high-dose methotrexate and fluorouracil combined with doxorubicin. A step ahead in the treatment of advanced gastric cancer: a trial of the European Organisation for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group. J Clin Oncol 1991, 9, 827-831.
26. 26. Kelsen D, Atiq OT, Saltz L, et al. FAMTX versus etoposide, doxorubicin, and cisplatin; a random assignment trial in gastric cancer. J Clin Oncol 1992, 10, 541-548.
27. 27. Bajetta E, Di Bartolomeo M, De Braud F, et al. Etoposide, doxorubicin and cisplatin (EAP) treatment in advanced gastric carcinoma: a multicentre study of the Italian Trials in Medical Oncology (ITMO) Group. Eur J Cancer 1994, 30A, 596-900.
28. 28. Cocconi G, Bella M, Zironi S, et al. FAM combination versus PELF combination (cisplatin, epirubicin, leucovorin, 5-fluorouracil) in advanced gastric cancer. A prospective randomized trial of the Italian Oncology Group for Clinical Research (GOIRC). J Clin Oncol 1994, 12, 2687-2693.
29. 29. Conti JA, Kemeny N, Seiter K, et al. Trial of sequential trimetrexate, fluorouracil, and high-dose leucovorin in previously treated patients with gastrointestinal carcinoma. J Clin Oncol 1994, 12, 695-700.
30. 30. Weh HJ, Wilke HJ, Dierlamm J, et al. Weekly therapy with folinic acid (FA) and high-dose 5-fluorouracil (5-FU) 24-hour infusion in pretreated patients with metastatic colorectal carcinoma. Ann Oncol 1994, 5, 233-237.
31. 31. Findlay M, Hill A, Cunningham D, et al. Protracted venous infusion 5-fluorouracil and interferon in advanced and refractory colorectal cancer. Ann Oncol 1994, 5, 239-243.
32. 32. Valone FH, Friedman MA, Wittlinger PS, et al. Treatment of patients with advanced colorectal carcinomas with fluorouracil alone, high-dose leucovorin plus fluorouracil, or sequential methotrexate, fluorouracil, and leucovorin: a randomized trial of the Northern California Oncology Group. J Clin Oncol 1989, 7, 1427-1436.
33. 33. Buroker R, O'Connell MJ, Wieand HS, et al. Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer. J Clin Oncol 1994, 12, 14-20.
34. 34. Falcone A, Pfanner E, Ricci S, et al. Oral doxifluridine in elderly patients with metastatic colorectal cancer: a muticenter phase II study. Ann Oncol 1994, 5, 760-762.
35. 35. Hryniuk WM. The importance of dose intensity in the outcome of chemotherapy. In De Vita VT Jr, Hellman S, Rosenberg SA, eds. Important Advances in Oncology 1988. Philadelphia, Lippin-cott, 1988, 125-128.